StockData
ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31

ALX ONCOLOGY HOLDINGS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.14+0.08 (+7.55%)

Close on Oct 19, 2026

Market cap
$154.63M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 6, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026Before market open–$-0.13–
Q1 FY2026
Ended Mar 31, 2026
May 8, 2026Before market open–$-0.17–
Q4 FY2025
Ended Dec 31, 2025
Feb 27, 2026Before market open–$-0.42–
Q3 FY2025
Ended Sep 30, 2025
Nov 7, 2025Before market open–––
Q2 FY2025
Ended Jun 30, 2025
Aug 12, 2025After market close–$-0.49–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025Before market open–––
Q4 FY2024
Ended Dec 31, 2024
Mar 6, 2025After market close–$-0.55–
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024After market close–$-0.58–
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024After market close–$-0.76–
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024After market close–$-0.71–
Q4 FY2023
Ended Dec 31, 2023
Mar 7, 2024After market close–$-0.93–

Press releases

Announcements Alx Oncology filed with the SEC